Vitae Pharmaceuticals Proposes Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Vitae Pharmaceuticals (VTAE) Sees 'Substantial' Costs for Developing VTP-43742, VTP-38543, VTP-36951
March 23, 2016 4:18 PM EDTVitae Pharmaceuticals (NASDAQ: VTAE) disclosed he following on Wednesday night:
ITEM 7.01. REGULATION FD DISCLOSURE.
On March 23, 2016, Vitae Pharmaceuticals, Inc. (Vitae) announced that Vitae currently anticipates that the net proceeds from the proposed public offering of its common stock,... More
